Report : North America Bioprocessing Market Forecast to 2031 - Regional Analysis - by Product (Instruments and Consumables & Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell & Gene Therapy, and Others), and End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others)
At 14.2% CAGR, North America Bioprocessing Market is Projected to be Worth US$ 35,950.43 Million by 2031, says Business Market Insights
According to Business Market Insights' research, the North America bioprocessing market was valued at US$ 12,440.60 million in 2023 and is expected to reach US$ 35,950.43 million by 2031, registering a CAGR of 14.2% from 2023 to 2031. Shift toward automated cell therapy manufacturing and proliferating demand for personalized medicine are among the critical factors attributed to drive the North America bioprocessing market growth.
A rising number of cell therapies have shifted the production of cell therapy products from a small volume to a large volume worldwide. Increasing research activities in cell therapies have led to a rise in the demand for advanced manufacturing solutions. In view of this, many players are offering products to meet the needs of academic researchers and large biotechnology companies. For instance, the Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are designed to enable the automation of most sequential unit operations for a CAR-T process within a single system. In addition, the evolution of cell therapy-from an academic and clinical setting to mass production and commercialization-is increasing the demand for automation in manufacturing. In May 2019, GE Healthcare launched the Chronicle web application to support the complete cell therapy workflow. Chronicle automation software is a good manufacturing practice-compliant digital solution designed to optimize complex cell therapy process development and manufacturing. Companies are also entering into strategic and technological developments for automation in cell therapy. For instance, in July 2020, Thermo Fisher Scientific Inc. and Lyell Immunopharma partnered to develop and manufacture processes to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve the fitness of T-cells and support the development of an integrated cGMP-compliant platform (system and software) along with reagents, consumables, and instruments. In March 2019, Lonza partnered with Israel's Sheba Medical Center to provide automated and closed CAR-T manufacturing using its point-of-care Cocoon cell therapy manufacturing platform. Automated procedures can drastically reduce the production cost and enhance staff productivity and retention rates. Other than these factors, automated processes restrict various possible sources of contamination in the manufacturing unit and eventually enhance process consistency, which results in overall good quality products by reducing manual errors. Thus, the increasing adoption of automation among cell therapy manufacturers and the growing product innovations in the field of cell therapy are likely to boost cell therapy bioprocessing or manufacturing.
On the contrary, stringent regulatory policies and limitations associated with bioprocessing hamper the growth of North America bioprocessing market.
Based on product, the North America bioprocessing market is bifurcated into instruments and consumables & accessories. The instruments segment held 67.4% market share in 2023, amassing US$ 8,384.46 million. It is projected to garner US$ 25,093.04 million by 2031 to register 14.7% CAGR during 2023-2031. Furthermore, the instruments segment is sub segmented into filtration devices, bioreactors, chromatography systems, centrifuge, drying devices, and others. Additionally, the bioreactors subsegment is categorized into pilot scale, full scale, and laboratory scale. Furthermore, the subsegment chromatography systems is segmented into liquid chromatography, gas chromatography, and others. Additionally, the consumables & accessories segment is subsegmented into reagents, cell culture media, chromatography resins, and others.
In terms of scale of operation, the North America bioprocessing market is bifurcated into commercial operations and clinical operations. The commercial operations segment held 81.6% share of North America bioprocessing market in 2023, amassing US$ 10,147.83 million. It is anticipated to garner US$ 30,194.71 million by 2031 to expand at 14.6% CAGR during 2023-2031.
By process, the North America bioprocessing market is bifurcated into downstream bioprocess and upstream bioprocess. The downstream bioprocess aids segment held 79.3% share of North America bioprocessing market in 2023, amassing US$ 9,870.59 million. It is projected to garner US$ 29,167.87 million by 2031 to expand at 14.5% CAGR from 2023 to 2031.
Based on application, the North America bioprocessing market is categorized into monoclonal antibodies, vaccines, recombinant protein, cell & gene therapy, and others. The monoclonal antibodies segment held 38.0% share of North America bioprocessing market in 2023, amassing US$ 4,731.31 million. It is predicted to garner US$ 12,775.46 million by 2031 to expand at 13.2% CAGR between 2023 and 2031.
In terms of end user, the North America bioprocessing market is categorized into biopharmaceutical companies, contract manufacturing organization, and others. The biopharmaceutical companies held 53.5% share of North America bioprocessing market in 2023, amassing US$ 6,659.79 million. It is estimated to garner US$ 19,539.49 million by 2031 to expand at 14.4% CAGR during 2023-2031.
By country, the North America bioprocessing market is segmented into the US, Canada, and Mexico. Our regional analysis states that the US captured 90.6% share of North America bioprocessing market in 2023. It was assessed at US$ 11,264.97 million in 2023 and is likely to hit US$ 33,185.84 million by 2031, registering a CAGR of 14.5% during 2023-2031.
Key players operating in the North America bioprocessing market are Getinge AB, Thermo Fisher Scientific Inc, Sartorius AG, Corning Inc, Bio-Rad Laboratories Inc, Merck KGaA, 3M Co, Eppendorf SE, Repligen Corp, Entegris Inc, Agilent Technologies Inc, and Cytiva US LLC, among others.
- In September 2023, Getinge AB launched a cutting-edge single-use bioreactor system, AppliFlex ST GMP. The system bridges the gap between research and clinical production in mRNA, cell, and gene therapies. The company's launch is a significant turning point since it offers researchers a turn-key, seamless solution to transfer bioprocesses from laboratory research to clinical applications.
- In February 2022, Thermo Fisher Scientific Inc announced an investment of US$ 40 million for the expansion of a single-use technology manufacturing facility in Millersburg, Penn. The manufacturing facility looks after critical materials used in developing new and existing biologics and vaccines, including COVID-19.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com